Takeda Pharmaceutical proposes $62bn acquisition of Shire to expand rare disease capabilities
Takeda Pharmaceutical, a major Japanese pharmaceutical company, has made a $62 billion offer to acquire Shire, an Ireland-based leader in rare disease treatments. This proposal, ... Read More
Procter & Gamble to acquire Merck’s consumer health business for €3.4bn
Procter & Gamble (P&G), a leading US consumer goods company, has finalized a deal to acquire the consumer health business of German pharmaceutical company Merck ... Read More
Servier Laboratories to acquire Shire’s oncology business for $2.4bn
In a strategic move to expand its global presence, French pharmaceutical giant Servier Laboratories has announced a $2.4 billion all-cash acquisition of the oncology business ... Read More
Sanofi to build new $396m vaccine manufacturing facility in Toronto
Significant Investment in Vaccine Production: French pharmaceutical giant Sanofi has announced plans to invest CAD 500 million (approximately $396.3 million) to construct a new vaccine ... Read More
Alexion Pharmaceuticals to acquire Wilson Therapeutics for $855m to enhance rare disease treatment options
In a significant move to expand its rare disease drug portfolio, U.S.-based Alexion Pharmaceuticals has announced an all-cash acquisition of Swedish pharmaceutical company Wilson Therapeutics ... Read More
GlaxoSmithKline transfers rare disease gene therapy portfolio to Orchard Therapeutics in strategic deal
GlaxoSmithKline (GSK), a leading British pharmaceutical company, has entered into a significant agreement with Orchard Therapeutics, transferring its rare disease gene therapy drugs in exchange ... Read More
Novartis to acquire AveXis for $8.7bn to expand gene therapy and neuroscience portfolio
Novartis, a Swiss pharmaceutical giant, has confirmed a substantial acquisition of AveXis, a US-based gene therapy company, for a total of $8.7 billion. This strategic ... Read More
GlaxoSmithKline to acquire full ownership of consumer healthcare venture from Novartis for $13bn
In a major strategic shift, GlaxoSmithKline (GSK) has finalized an agreement to acquire Novartis' 36.5% stake in their consumer healthcare joint venture for $13 billion. ... Read More
Pfizer faces setback as Reckitt Benckiser and GSK withdraw from $20bn consumer health deal
Pfizer's $20 Billion Sale Stalls: In a significant turn of events in the pharmaceutical industry, both Reckitt Benckiser and GlaxoSmithKline (GSK) have decided to withdraw ... Read More
Lundbeck to acquire Prexton Therapeutics in $1.1bn deal to expand Parkinson’s Disease treatment portfolio
Lundbeck, a leading Danish pharmaceutical company, has announced its acquisition of Prexton Therapeutics, a Swiss firm specializing in the development of drugs for Parkinson's disease, ... Read More